| Literature DB >> 28608432 |
Satsuki Fukushima1, Motohide Uemura2, Kunihito Gotoh3, Takeshi Ujike2, Hiroshi Wada3, Shigeru Miyagawa1, Koichi Toda1, Yoshiki Sawa1.
Abstract
BACKGROUND AND OBJECTIVES: For tumor thrombus in the inferior vena cava (IVC) complicated with kidney cancer, we built a surgical team to achieve (1) en bloc tumor resection; (2) xeno-pericardial patch IVC repair; and (3) minimum organ damages. We reviewed outcome of the case series to verify rationale of this approach.Entities:
Keywords: IVC tumor thrombus; renal cell carcinoma; surgical team
Mesh:
Year: 2017 PMID: 28608432 PMCID: PMC5724493 DOI: 10.1002/jso.24709
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454
Figure 1The tip of the tumor thrombus and the area of the IVC wall that was adhered by the tumor thrombus was examined direct ultrasonography study, by which final decision was made to select one of the three surgical procedures. Incision of the IVC was started in the tumor‐free IVC wall at the level of the renal vein, and extended longitudinally to identify the tips of the tumor thrombus with 5 mm tumor‐free margin remaining in the IVC wall
Figure 2(A) The inferior vena cava (IVC) was repaired by glutaraldehyde‐treated bovine pericardial patch after the removal of IVC tumor thrombus under the view of liver mobilization. (B) The tumor was removed en bloc including the tumor‐thrombus and the diseased kidney
Figure 3(A) In the cases in which the tip of the tumor thrombus was present below the stem of the hepatic veins, the clamps were placed on the infrahepatic inferior vena cava (IVC), the infrarenal IVC, and the left renal vein, with or without clamp on the left renal artery, to expose the IVC that was longitudinally incised under minimum time of kidney ischemia without liver ischemia (The Procedure I). (B) In the cases in which the tip of the tumor thrombus was present in the intrahepatic IVC, the clamps were placed in the suprahepatic IVC, the hepatic veins, the infrarenal IVC, and the left renal artery/vein to expose the IVC that was longitudinally incised under the liver and the kidney ischemia (The Procedure II). Median sternotomy may be added depending upon the exposure of the suprahepatic IVC. (C) In the cases in which the tumor thrombus was present in the right atrium, extracorporeal circulation with mild hypothermia was established to expose the IVC and the right atrium that was longitudinally incised under induced ischemia in the liver and the left kidney (The Procedure III)
Preoperative characteristics
| Age | Gender | Clinical stage | Distant metastasis | Novick class | Neves class | Tumor side | Serum creatinine (mg/dL) | eGFR | |
|---|---|---|---|---|---|---|---|---|---|
| Procedure I | |||||||||
| Case 1 | 60 | Male | T3bN1M1 | Lung | II | I | Right | 1.27 | 46.1 |
| Case 2 | 68 | Male | T3bN0M0 | No | II | I | Right | 0.99 | 58.4 |
| Case 3 | 66 | Female | T3aN2M1 | Lung | II | II | Right | 0.65 | 69 |
| Case 4 | 65 | Male | T3bN0M0 | No | II | II | Right | 1.21 | 47.5 |
| Case 5 | 69 | Male | T4N0M1 | Lung | II | II | Right | 0.91 | 63.8 |
| Procedure II | |||||||||
| Case 6 | 67 | Male | T3cN0M0 | No | III | III | Right | 1.56 | 35.7 |
| Case 7 | 80 | Female | T3bN0M0 | No | II | II | Right | 0.52 | 83.4 |
| Case 8 | 43 | Female | T3bN0M0 | No | III | III | Right | 0.89 | 55.3 |
| Case 9 | 78 | Male | T3bN0M0 | No | II | II | Right | 1.67 | 31.3 |
| Case 10 | 65 | Female | T3cN0M1 | Lung, liver | III | III | Right | 0.77 | 57.6 |
| Procedure III | |||||||||
| Case 11 | 73 | Male | T3cN0M0 | No | IV | IV | Right | 0.9 | 63.5 |
| Case 12 | 72 | Male | T3cN0M0 | No | IV | IV | Right | 0.87 | 66.2 |
eGFR; estimated glomerular filtration rate.
Surgical details
| Organ ischaemia (min) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sternotomy | Liver detachment | Additional procedure | IVC clamp (min) | Liver | Kidney | Extra‐ corporeal circulation (min) | Distal IVC | Red blood cell transfusion (Unit) | |
| Procedure I | |||||||||
| Case 1 | No | No | No | 20 | 0 | 5 | N/A | Repaired | 12 |
| Case 2 | No | No | No | 15 | 0 | 13 | N/A | Reparied | 0 |
| Case 3 | No | Yes | No | 22 | 0 | 5 | N/A | Repaired | 4 |
| Case 4 | No | Yes | Ascending colectomy | 27 | 0 | 0 | N/A | Reparied | 6 |
| Case 5 | No | Yes | No | 26 | 0 | 0 | N/A | Repaired | 5 |
| Procedure II | |||||||||
| Case 6 | Yes | Yes | No | 40 | 24 | 37 | N/A | Stumped | 18 |
| Case 7 | Yes | Yes | Hepatic artery repair | 35 | 5 | 30 | N/A | Reparied | 6 |
| Case 8 | No | Yes | No | 30 | 20 | 30 | N/A | Stumped | 16 |
| Case 9 | No | Yes | No | 40 | 16 | 29 | N/A | Stumped | 8 |
| Case 10 | No | Yes | Ileocecal resection | 35 | 14 | 30 | N/A | Repaired | 16 |
| Procedure III | |||||||||
| Case 11 | Yes | Yes | No | 50 | 25 | 45 | 79 | Repaired | 12 |
| Case 12 | Yes | Yes | CABG | 65 | 29 | 60 | 161 | Reparied | 28 |
Postopetaive outcome
| 30‐Day Clavien‐Dindo class | Max ALT (U/L) | Max total bilirubin (mg/dL) | Max creatinine (mg/dL) | Min eGFR | Creatinine at discharge (mg/dL) | eGFR at discharge | Days till discharge | |
|---|---|---|---|---|---|---|---|---|
| Procedure I | ||||||||
| Case 1 | II | 92 | 1.1 | 1.47 | 39.3 | 1.5 | 38.4 | 33 |
| Case 2 | II | 377 | 0.7 | 1.41 | 39.7 | 0.94 | 61.8 | 33 |
| Case 3 | II | 43 | 1.7 | 1.1 | 38.8 | 0.9 | 48.3 | 18 |
| Case 4 | II | 31 | 0.6 | 2.64 | 20.2 | 1.37 | 41.5 | 25 |
| Case 5 | II | 69 | 0.5 | 1.25 | 45.1 | 1.01 | 56.9 | 23 |
| Procedure II | ||||||||
| Case 6 | II | 213 | 2 | 1.77 | 31.1 | 1.36 | 34 | 30 |
| Case 7 | II | 523 | 3.8 | 1.11 | 36.4 | 0.72 | 58.4 | 82 |
| Case 8 | II | 121 | 1.9 | 1.14 | 42.2 | 0.88 | 56 | 72 |
| Case 9 | II | 76 | 1 | 1.85 | 28.5 | 1.71 | 30.9 | 18 |
| Case 10 | II | 44 | 2.8 | 0.77 | 57.6 | 0.88 | 49.7 | 25 |
| Procedure III | ||||||||
| Case 11 | II | 63 | 1.1 | 1.24 | 44.8 | 0.9 | 63.5 | 22 |
| Case 12 | II | 67 | 1.7 | 1.62 | 33.5 | 1.02 | 55.6 | 47 |
ALT; alanine transaminase, eGFR; estimated glomerular filtration rate.
Oncological outcome
| Postop oncological therapy | Latest status | Cause of death | Follow up post‐surgery (Day) | Recurrence | Tumor free days post‐surgery | |
|---|---|---|---|---|---|---|
| Procedure I | ||||||
| Case 1 | Sunitinib | Alive | 555 | Lung | 0 | |
| Case 2 | No | Alive | 527 | No | 527 | |
| Case 3 | Sunitinib | Alive | 61 | Lung | 0 | |
| Case 4 | No | Alive | 28 | No | 28 | |
| Case 5 | Sunitinib | Alive | 14 | Lung | 0 | |
| Procedure II | ||||||
| Case 6 | No | Alive | 579 | No | 579 | |
| Case 7 | No | Deceased | Pneumonia | 223 | No | 223 |
| Case 8 | Sunitinib | Deceased | Recurrence | 550 | Lung, bone | 102 |
| Case 9 | No | Alive | 377 | Bone | 277 | |
| Case 10 | Sunitinib | Alive | 403 | Lung, liver | 0 | |
| Procedure III | ||||||
| Case 11 | No | Alive | 628 | No | 628 | |
| Case 12 | No | Deceased | Recurrence | 75 | Lung, liver | 28 |